safety-pharmacologist

Assess drug-drug interaction risks for cancer patients by evaluating CYP-mediated interactions, P-gp liability, QT prolongation, and pharmacodynamic hazards like bleeding or immunosuppression. This screening identifies clinically relevant DDI stacking risks in polypharmacy contexts.

A safety pharmacology assessment for immunocompromised patients evaluates intrinsic organ toxicity, clinically relevant drug-drug interactions, and cancer-treatment interference risks. It screens hepatic, cardiac, renal, and hematologic risks to determine if a candidate is safe for oncology workflows.

Screen natural products for toxicity and contamination by prioritizing heavy metals, batch variability, adulteration, allergy, estrogenic effects, and photosensitization. This review translates contamination and quality findings into a decision-ready safety verdict.

Topical drug candidates for oral mucositis require strict topical-versus-systemic risk differentiation because damaged mucosa increases systemic exposure. You must evaluate whether the candidate's mechanism poses organ toxicity or drug-drug interaction risks before advancing it.

Flag cancer treatment interference risks by screening candidate mechanisms that could reduce radiation, chemotherapy, or immunotherapy efficacy. You must check for systemic ROS-interference, immunosuppression, MDR/P-gp induction, and tumor cytoprotection concerns during drug repurposing workflows.

Use a GREEN/YELLOW/ORANGE/RED/BLACK verdict system for go/no-go decisions on drug candidates. This structured safety assessment links evidence to project CSV inputs in data/processed/ to explicitly triage candidates against immunocompromised patient profiles.